Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO-BLISOVI FE vs DEMULEN 1/50-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
Prevention of pregnancy,Treatment of heavy menstrual bleeding (off-label),Acne vulgaris (off-label)
FDA: Prevention of pregnancy,Off-label: Treatment of acne vulgaris, dysmenorrhea, endometriosis-related pain, menstrual irregularity
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet orally once daily for 28 consecutive days per cycle.
Terminal elimination half-life: 15-18 hours for ethinyl estradiol; clinical context: supports once-daily dosing
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Hepatic via CYP3A4 (ethinyl estradiol) and primarily conjugation (norethindrone); first-pass metabolism.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism with sulfation and glucuronidation. Ethynodiol diacetate: Deacetylated to norethynodrel, then extensively metabolized via reduction and conjugation.
Renal (approximately 60% as metabolites, 10-15% as unchanged drug); fecal (about 20-30%)
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
Ethinyl estradiol: 95-98% bound to albumin and sex hormone-binding globulin (SHBG)
Ethinylestradiol: >97% bound, primarily to albumin, with ~2% bound to sex hormone-binding globulin (SHBG); ethynodiol diacetate (as norethindrone): ~95% bound, primarily to albumin and SHBG.
Ethinyl estradiol: 2-5 L/kg; indicates extensive tissue distribution
Ethinylestradiol: Vd ~2-4 L/kg; distributes extensively into body tissues; ethynodiol diacetate (as norethindrone): Vd ~4 L/kg; indicates wide distribution including reproductive tissues.
Oral: ethinyl estradiol approximately 40-50% (first-pass metabolism)
Oral: ethinylestradiol bioavailability ~40-60% due to first-pass metabolism; ethynodiol diacetate bioavailability ~60-80% after oral administration.
No dose adjustment required in renal impairment. Use with caution if severe renal impairment or nephrotic syndrome due to potential fluid retention.
No dosage adjustment required for renal impairment. Use is not recommended in patients with severe renal impairment due to potential adverse effects.
Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh class C). Not recommended in moderate impairment (Child-Pugh B) without specialist advice. No data for mild (Child-Pugh A); use caution.
Contraindicated in patients with Child-Pugh C cirrhosis. For Child-Pugh A or B, use is generally not recommended; if used, monitor closely for adverse effects.
Not indicated in pediatric patients before menarche. For postmenarchal females, same adult dose may be used; weight-based dosing not established.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 28 days per cycle.
Not indicated in postmenopausal women. No specific geriatric dose adjustments; consider increased risk of thrombotic events and comorbidities.
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly, but consider increased risk of thromboembolic disorders.
Cigarette smoking increases risk of serious cardiovascular events from COC use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (DVT, PE, stroke, MI),Carcinoma (breast, cervical, liver),Hepatic disease (jaundice, cholestasis),Hypertension,Carbohydrate/lipid effects,Headache/migraine,Bleeding irregularities,Drug interactions (CYP3A4 inducers/inhibitors),Depression,Gallbladder disease,Hereditary angioedema
Thromboembolic disorders (DVT, PE, stroke, MI),Hepatic neoplasia (benign/malignant liver tumors),Increased risk of gallbladder disease,Hypertension,Carbohydrate/lipid metabolic effects,Ocular disturbances (retinal thrombosis, optic neuritis),Depression,Fetal harm if used during pregnancy
Venous or arterial thrombotic/thromboembolic events (current or history),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Uncontrolled hypertension,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Headache with focal neurological symptoms or migraine with aura (age ≥35),Current or history of breast cancer or other estrogen-sensitive neoplasia,Hepatic adenomas or malignant liver tumors,Acute or chronic liver disease with abnormal function,Undiagnosed abnormal uterine bleeding,Known or suspected pregnancy,Cigarette smoking in women >35 years,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Grapefruit juice may increase estrogen levels and risk of adverse effects; avoid large quantities. Iron absorption is enhanced by vitamin C (e.g., orange juice) and inhibited by tannins (tea, coffee), calcium (dairy), and phytates (whole grains); separate iron intake from these foods by at least 2 hours. Take with food to reduce GI upset.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is unclear. Maintain consistent intake of vitamin C-rich foods as they may increase estrogen absorption. Avoid St. John's wort, which reduces contraceptive efficacy.
Pregnancy category X. Combination hormonal contraceptives are contraindicated in pregnancy due to known risks to the fetus, including cardiovascular and limb defects from first-trimester exposure, and potential feminization of male fetuses from progestin exposure. Post-conception use is not indicated; if exposure occurs, evaluate for pregnancy.
Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimesters: association with masculinization of female fetus, adrenal suppression, and possible long-term metabolic effects. Estrogen component may increase risk of VACTERL anomalies.
Small amounts of progestins and estrogens are excreted in breast milk; M/P ratio not established for this specific formulation. Use in breastfeeding women is generally not recommended due to potential effects on milk production and composition, and possible long-term effects on the infant. Alternative contraception methods are advised until weaning.
Contraindicated during breastfeeding. Estrogens reduce milk production and quality. M/P ratio not established; ethinyl estradiol and norgestrel are excreted in breast milk in small amounts, potentially causing adverse effects in the infant.
Contraindicated in pregnancy. If pregnancy occurs, discontinue immediately. No dose adjustment is applicable as the drug should not be used in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) are irrelevant due to contraindication.
No adjustments; absolute contraindication in pregnancy. Drug should be discontinued immediately upon pregnancy diagnosis. No established safe dose in pregnancy.
LO-BLISOVI FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is a combined oral contraceptive with iron supplementation. The iron component (75 mg ferrous fumarate) compensates for menstrual blood loss. Administer at the same time daily to maintain stable hormone levels. Missed doses increase risk of breakthrough bleeding and contraceptive failure. Consider non-oral contraceptives in patients with malabsorption or vomiting.
Demulen 1/50-28 is a monophasic combined oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Due to the 50 mcg estrogen dose, it carries an increased risk of venous thromboembolism compared to lower-dose pills; avoid in patients with migraine with aura, hypertension >160/100 mm Hg, or age >35 who smoke. The 28-day pack includes 21 active pills and 7 placebo pills; breakthrough bleeding is more common with higher estrogen. Caution with hepatic enzyme inducers like rifampin or anticonvulsants may reduce efficacy.
Take one tablet daily at the same time with food to reduce nausea.,Missed doses: if one dose is missed >12 hours, take it immediately and continue; if two doses are missed, take two tablets and use backup contraception for 7 days.,Iron tablets may cause dark stools; this is harmless.,Report severe headache, chest pain, leg swelling, or vision changes immediately.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Store in original blister pack; do not remove desiccant.
Take one pill daily at the same time, preferably with food to reduce nausea.,The first 7 days of the first cycle require a backup contraceptive method if not starting on day 1 of menses.,Missed pill: if one active pill is missed, take it as soon as remembered and continue; if two or more active pills are missed, take the last missed pill, skip the others, use backup for 7 days, and consider emergency contraception.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,The 7 placebo pills are for withdrawal bleeding; start next pack on time regardless of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO-BLISOVI FE vs DEMULEN 1/50-28, answered by our medical review team.
LO-BLISOVI FE is a Combination Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.. DEMULEN 1/50-28 is a Combination Oral Contraceptive that works by Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO-BLISOVI FE and DEMULEN 1/50-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO-BLISOVI FE is: One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.. The standard adult dose of DEMULEN 1/50-28 is: One tablet orally once daily for 28 consecutive days per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO-BLISOVI FE and DEMULEN 1/50-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO-BLISOVI FE is classified as Category C. Pregnancy category X. Combination hormonal contraceptives are contraindicated in pregnancy due to known risks to the fetus, including cardiovascular and limb defects from first-tri. DEMULEN 1/50-28 is classified as Category C. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.